1. Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice
- Author
-
Palladino, Claudia, Gómez, María Luisa Navarro, Soler-Palacín, Pere, González-Tomé, María Isabel, De Ory, Santiago J., Espiau, María, Hoyos, Santiago Pérez, León-Leal, Juan Antonio, Méndez, María, Moreno-Pérez, David, Guasch, Claudia Fortuny, Sierra, Antoni Mur, Guruceta, Itziar Pocheville, Guillén, Santiago Moreno, and Briz, Verónica
- Abstract
Supplemental Digital Content is available in the textMaraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs.
- Published
- 2015
- Full Text
- View/download PDF